FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1243-1245 October 23, 1997 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The EPIC Investigators Related Article by The EPILOG Investigators

To the Editor: Although antagonists of the platelet glycoprotein IIb/IIIa receptor are undoubtedly efficacious in selected patients undergoing angioplasty, we believe there is an alternative perspective to that of the Evaluation in PTCA to Improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade (EPILOG) investigators (June 12 issue)¹ and Dr. Holmes, who wrote the accompanying editorial.² The investigators concluded that this agent may have "potentially broad clinical use" in patients undergoing percutaneous transluminal coronary angioplasty (PTCA), and Dr. Holmes designated the trial a "home run."

The primary finding in the EPILOG trial was a reduction in the need for urgent revascularization . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.